As many as 250,000 people in the US have dystonia, making it the third most common movement disorder following essential tremor and Parkinson's disease.

This authoritative reader-friendly resource provides a wide-ranging overview of the latest research and developments regarding the pathogenesis, evaluation, and management of the disease. Offering detailed coverage of every available treatment option for dystonia, including four categorized sections on medical management, botulinum toxin injections, phenol or neurolytic therapy, and surgical intervention.

This source summarizes what is known about the disorder and dramatically improves the recognition and understanding of this debilitating disease.The most important update to the second edition is the addition of four new chapters dedicated to the discussion of individual botulinum toxins recently approved to treat dystonia: Botox, Myobloc, Disport, and Xeomin. Other new chapters include a discussion of rapid-onset dytonia-parkinson’s, dystonic synptoms associated with parkinson’s disorders, the use of Transcranial Magnetic Stimulation (TMS) as a treatment option for dystonia, as well as a chapter dedicated to spasticity, its pathogenesis, evaluation, and treatment with toxins, other injectables or surgical therapies.

Filling a gap in the literature, this reference:

• Reviews the genetic factors of dystonia, as well as supplies in-depth coverage of the neuroanatomy, neurophysiology, and neuropathology of the disease
• Reviews secondary causes of dystonia including drug-induced and psychogenic presentations
• Devotes a chapter to non-motor symptoms relating to movement disorders
• Contains three chapters focusing on botulinum toxin in the treatment of dystonic disorders
• Analyzes surgical approaches for treatment including deep brain stimulation for various types of dystonia
• Contains clinical descriptions of idiopathic and task-specific dystonias